EMPHARM-NET

Emergency Medicine PHARMacotherapy research NETwork 🚨 Pushing the EM PharmD profession forward through high quality, collaborative research 📄

[EMPHARM-NET @EMPHARM_NET]

@MeganARech @bfaine1

[EMPHARM-NET @EMPHARM_NET]

📢Check out our new publication on forming & maintaining a research network: Emergency Medicine PHARMacotherapy research NETwork (EMPHARM-NET), established to unify investigators, foster mentorship, & advance high-quality EM research https://t.co/6hWPIWuYa3

[EMPHARM-NET @EMPHARM_NET]

📣 Calling all EM clinicians: please take our IRB-approved anonymous survey examining awareness & experience with anti-amyloid therapies

Survey link: https://t.co/6k8cz56IQp

We aim to reach a broad EM audience to characterize awareness of AATs & compile innovative strategies

[Megan Rech, PharmD, MS @MeganARech]

@bfaine1 & I penned an editorial called Pharmacists on the Front Lines: Advances in Emergency Medicine Pharmacy Practice on the history and advancement of EM pharmacy culminating in this EM themed issue🚨

https://t.co/GcMwfHPFQ8

[Megan Rech, PharmD, MS @MeganARech]

Excited to share the Emergency Medicine themed issue of @ASHPOfficial @AJHPOfficial that I guested edited w/ @bfaine1.

20 ( ‼️ ) papers & >50 EM pharmacists - this is a testament to how talented and diverse our EM pharmacy community is!

Read here 👉https://t.co/hh4Hxzwq4T

[Megan Rech, PharmD, MS @MeganARech]

💡 Need one more reason to love your friendly EM pharmacist? Check out this @EMPHARM_NET SR/MA:

⏰ EMP presence was associated with reduced mean DTN time by 14.6 minutes (95 % CI -18.1, −11.1 min)

Time for @American_Stroke @American_Heart to take notice?

[EMPHARM-NET @EMPHARM_NET]

Check out our new SR/MA on the benefits of an EM pharmacist on thrombolytic DTN time in acute ischemic stroke 🧠

[Kevin Mercer, PharmD, MPH @ohsnapimginger]

Just published in #AJEM! 📄

#PhAST1 is the first systematic review & meta-analysis quantifying the impact of #EMPharmD on stroke #doortoneedle times 🧠🚑

📉 Faster treatment
🤝 More interprofessionalism
🏥 Justification for expanding #EMPharmD services

https://t.co/OHa5ayEFkb

[EMPHARM-NET @EMPHARM_NET]

Lead by @DEZ_EM_Pharm

@MeganARech @LizVanwert @bfaine1

[EMPHARM-NET @EMPHARM_NET]

🔥 New study HBV s/p sexual assault:

🏥 1010 patients, 10 @EMPHARM_NET EDs
💉 62.7 % with no/unknown vaccine history - only 5.8% received HBV vaccine
🧪 HBV serology testing 63.6%
🦠 8 patients received HBIG
🚨 Room for improvement in HBV care

Free link: https://t.co/oq0RgcRnsd

[EMPHARM-NET @EMPHARM_NET]

🔥 Off the Press: Risk factors for enterococcal UTI in ED patients (n=1836, 5% Enterococcus)

🧪 Combination of positive leukocyte esterase (LE+) and negative nitrite (NI−)  significantly associated w/ Enterococcus UTI (aOR 7.1, 95 % CI 3.73–13.5)

 https://t.co/5975lF1GFz

[Megan Rech, PharmD, MS @MeganARech]

📣Have you heard of antiamyloid therapies for AD? They cause ADEs called ARIAs that are non-specific, typically require MRI & can mimic stroke

⛔ Concomitant thrombolytics/anticoagulants are contraindicated

Learn more in our JAMA IM Clinical Insight👉 https://t.co/AvDR0CZ8py

[Megan Rech, PharmD, MS @MeganARech]

So excited to announce that @SAEM_AEMP is officially an @SAEMonline Academy! Thanks so everyone who worked so hard to get us to this point & continue to promote our mission of advancing EM pharmacy practice! So grateful to work with all of you! @LRayRx @EmergPharm

[SAEM AEMP @SAEM_AEMP]

🎉 Big news from #SAEM25 -- AEMP is officially transitioning to an academy within SAEM!!
🥳 We are so excited for the opportunities this will offer us!
🥂 Thankful for all our members & the group of EM pharmacist leaders who made this possible!!
#AEMPlify #AEMP25 @SAEMonline

[EMPHARM-NET @EMPHARM_NET]

Hot off the press: 🔥
New EMPHARM-NET study on desmopressin administration in antiplatelet-related ICH. Link here 👇

[Megan Rech, PharmD, MS @MeganARech]

🔥New @EMPHARM_NET DONT EXPAND Study:
💊Propensity-matched, 11 EDs: desmopressin (n=35) vs. controls (n=140)
😷Desmo patients had higher baseline ICH volumes
🧠No difference in good or excellent hemostatic efficacy assessed via hematoma volume measures
https://t.co/E3Z0TC3QvY

[EMPHARM-NET @EMPHARM_NET]

📣Check out our latest publication📣

The 2024 EM Pharmacotherapy literature review is here. Check out the most impactful studies of the last year 👇

[Ryan Feldman (empoisonpharmd.bsky.social) @EMPoisonPharmD]

🚨 Just published in AJEM from @EMPHARM_NET:

CuratED: The 2024 Emergency Medicine Drug Lit Review

🔥 11 RCTs
📜 10 guidelines
🔍 7 meta-analyses
💊 DAPT & stroke, steroids & CAP, TXA & ICH, Andexxa & more

Stay EM Pharm sharp👇
🔗 https://t.co/tejQKt6KQO

#FOAMed #MedED

[EMPHARM-NET @EMPHARM_NET]

Our COPY-ED study was highlighted in NEJM Journal Watch: https://t.co/eqkrxzYUjl

@bfaine1 @ThePeoplesRuben @giles_slocum @DEZ_EM_Pharm @gavin_howington @AM_EM_PharmD @annezepeski @MeganARech

[EMPHARM-NET @EMPHARM_NET]

@ThePeoplesRuben @AP_EMPharmD @EMPoisonPharmD @giles_slocum @DEZ_EM_Pharm @gavin_howington @AM_EM_PharmD @CBthePHARMD @annezepeski @MeganARech

[EMPHARM-NET @EMPHARM_NET]

🔥Hot off the press: @EMPHARM_NET COPY-ED Study:
💊 Oral cephalosporins (n=647) vs IDSA guideline concordant FQ or TMP-SMX (n=204) for pyelonephritis in patients discharged from the ED
🙅‍♀️No difference in 14 d treatment failure
@jlkoehl @bfaine1
https://t.co/NDZbMlv88A

[Megan Rech, PharmD, MS @MeganARech]

🚨Should sugammadex be used to reverse the effects of rocuronium in the ED? 🚨

Check out our new @AnnalsofEM Clinical Controversy to learn why you should use it:
https://t.co/UnOHcM4lor
@MGottliebMD

🥊Opposing side coming soon from @EmergPharm & @AM_EM_PharmD

[Kyle DeWitt @EmergPharm]

🥊 Sugammadex should NOT be routinely used to reverse to reverse rocuronium for patients in the ED with @AM_EM_PharmD

https://t.co/recGI6X1rs

Shout out to @MeganARech and @MGottliebMD for their take on the pro side!